Eli Lilly and Company: Breast Neoplasms trials
The registry lists 88 Breast Neoplasms studies with Eli Lilly and Company as lead sponsor. 7 are open to participants now and 48 have results posted.
Phase 1 23Phase 2 47Phase 3 16Phase 4 4No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingNCT07935317Phase 2
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingNCT07287098Phase 2
- A Study of LY4337713 in Participants With FAP-Positive Solid TumorsRecruitingNCT07213791Phase 1
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2
- Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerActive, not recruitingNCT05169567Phase 3Results posted
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerTerminatedNCT04752332Phase 3Results posted
- A Study of Abemaciclib in Indian Women With Advanced Breast CancerCompletedNCT04707196Phase 4Results posted
- A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryCompletedNCT04647487Phase 1Results posted
- A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerTerminatedNCT04031885Phase 4Results posted
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast CancerCompletedNCT03703466Phase 2Results posted
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
- Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerActive, not recruitingNCT03155997Phase 3Results posted
- A Study of AK-01 (LY3295668) in Solid TumorsCompletedNCT03092934Phase 1/2Results posted
- A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT02784795Phase 1Results posted
- A Study of Abemaciclib (LY2835219) in Participants With Breast CancerActive, not recruitingNCT02763566Phase 3Results posted
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast CancerCompletedNCT02747004Phase 2Results posted
- A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerCompletedNCT02675231Phase 2Results posted
- A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerCompletedNCT02441946Phase 2Results posted
- A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerActive, not recruitingNCT02246621Phase 3Results posted
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingNCT02107703Phase 3Results posted
- A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has SpreadCompletedNCT02102490Phase 2Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-CisplatinCompletedNCT01606748Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast CancerCompletedNCT01427933Phase 2Results posted
- A Study of LY2523355 in Participants With Breast CancerCompletedNCT01416389Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) in Participants With Breast CancerCompletedNCT01256567Phase 1Results posted
- Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer PatientsCompletedNCT01234402Phase 2Results posted
- A Study of LY573636-sodium in Patients With Metastatic Breast CancerCompletedNCT00992225Phase 2Results posted
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast CancerCompletedNCT00728949Phase 2Results posted
- Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast CancerCompletedNCT00703326Phase 3Results posted
- Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast CancerCompletedNCT00623233Phase 2Results posted
- Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast CancerTerminatedNCT00536939Phase 2Results posted
- Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast CancerCompletedNCT00451555Phase 2Results posted
- Enzastaurin in Combination of Capecitabine to Treat Breast CancerTerminatedNCT00437294Phase 2Results posted
- Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast CancerCompletedNCT00334802Phase 2Results posted
- Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast CancerCompletedNCT00325234Phase 2Results posted
- A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast CancerCompletedNCT00320541Phase 2Results posted
- Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast CancerCompletedNCT00316199Phase 2Results posted
- Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBCCompletedNCT00236899Phase 3Results posted
- Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st LineCompletedNCT00191854Phase 2Results posted
- Combination Chemotherapy for Metastatic Breast CancerCompletedNCT00191815Phase 2Results posted
- Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast CancerCompletedNCT00191789Phase 2Results posted
- A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast CancerCompletedNCT00191451Phase 2Results posted
- Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane RegimenCompletedNCT00191269Phase 2Results posted
- A Phase III Trial For Patients With Metastatic Breast CancerCompletedNCT00191152Phase 3Results posted
- A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer PatientsCompletedNCT00190671Phase 1/2Results posted
- Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment RegimensCompletedNCT00149214Phase 2Results posted
- Pemetrexed as the First Treatment in Advanced or Metastatic Breast CancerCompletedNCT00106002Phase 2Results posted
- Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane TherapyCompletedNCT00063570Phase 2Results posted
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingNCT05514054Phase 3
- A Study of LY3484356 in Chinese Participants With Advanced Breast CancerActive, not recruitingNCT05509790Phase 1
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1
- A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWithdrawnNCT03988114Phase 4
- A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the BodyCompletedNCT03955939Phase 1
- Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationApproved for marketingNCT03906331
- Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerApproved for marketingNCT03763604
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
- Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerApproved for marketingNCT02792725
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedNCT02791334Phase 1
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingNCT02779751Phase 1
- A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerCompletedNCT02124148Phase 1
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingNCT02057133Phase 1
- A Study of LY3023414 in Participants With Advanced CancerCompletedNCT01655225Phase 1
- Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane ChemotherapyCompletedNCT00386087Phase 2
- Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or TaxanesCompletedNCT00192101Phase 2
- A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast CancerCompletedNCT00192062Phase 2
- A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast CancerCompletedNCT00191672Phase 2
- Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic AgentsCompletedNCT00191438Phase 3
- A Trial for HER2 Positive Breast Cancer Patients With Metastatic DiseaseCompletedNCT00191373Phase 2
- A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast CancerCompletedNCT00191347Phase 2
- Docetaxel vs. Docetaxel-Gemcitabine in Breast CancerCompletedNCT00191243Phase 2
- A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue TreatmentCompletedNCT00190697Phase 4
- Raloxifene Use for The HeartCompletedNCT00190593Phase 3
- A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast CancerCompletedNCT00102219Phase 2
- Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00097383Phase 1/2
- Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast CancerCompletedNCT00072865Phase 2
- Pemetrexed as First Line Chemotherapy for Advanced Breast CancerCompletedNCT00065533Phase 2
- A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.CompletedNCT00034489Phase 2
- Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.CompletedNCT00034125Phase 3
- Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast CancerCompletedNCT00006459Phase 3